Skip to content
Summit Therapeutics nominates CARB-X-funded SMT-571 as lead clinical candidate for treatment of gonorrhoea
Full Story
We use cookies to ensure that we give you the best experience on our website. By clicking “Ok”, you consent to the use of all cookies.Ok
Toggle navigation